Cigna Investments Inc. New trimmed its holdings in Mylan NV (NASDAQ:MYL) by 8.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,554 shares of the company’s stock after selling 1,227 shares during the period. Cigna Investments Inc. New’s holdings in Mylan were worth $291,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. World Asset Management Inc grew its stake in Mylan by 6.3% in the 3rd quarter. World Asset Management Inc now owns 37,220 shares of the company’s stock valued at $736,000 after buying an additional 2,203 shares in the last quarter. State Street Corp grew its stake in Mylan by 2.4% in the 3rd quarter. State Street Corp now owns 22,959,707 shares of the company’s stock valued at $454,143,000 after buying an additional 547,356 shares in the last quarter. Pictet Asset Management Ltd. grew its stake in Mylan by 7.4% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,500,982 shares of the company’s stock valued at $29,689,000 after buying an additional 103,800 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Mylan by 91.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 2,089,240 shares of the company’s stock valued at $41,325,000 after buying an additional 996,732 shares in the last quarter. Finally, Huntington National Bank purchased a new position in Mylan in the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 85.89% of the company’s stock.

MYL has been the subject of a number of recent analyst reports. Evercore ISI restated a “buy” rating on shares of Mylan in a research report on Monday, December 16th. ValuEngine upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. SunTrust Banks restated a “buy” rating and set a $27.00 price target on shares of Mylan in a research report on Wednesday, February 5th. Piper Sandler initiated coverage on shares of Mylan in a research report on Thursday, January 9th. They set a “neutral” rating and a $21.00 price target for the company. Finally, Royal Bank of Canada boosted their price target on shares of Mylan from $25.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 6th. Twelve investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $26.92.

Mylan stock opened at $21.64 on Friday. The company has a quick ratio of 0.84, a current ratio of 1.43 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $11.67 billion, a PE ratio of 240.47, a P/E/G ratio of 1.37 and a beta of 1.72. The firm has a fifty day simple moving average of $21.36 and a two-hundred day simple moving average of $19.69. Mylan NV has a twelve month low of $16.63 and a twelve month high of $32.23.

In other news, insider Paul Campbell sold 11,611 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $23.00, for a total transaction of $267,053.00. Following the completion of the transaction, the insider now directly owns 37,024 shares of the company’s stock, valued at $851,552. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.82% of the company’s stock.

Mylan Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Featured Article: What do I need to know about analyst ratings?

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.